Survival of patients with ovarian epithelial carcinomas after second-look laparotomy

Edward Podczaski, Alberto Manetta, Paul Kaminski, Antonio Ricelli, James Larson, Koenraad De Geest, Rodrigue Mortel

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Survival of ovarian carcinoma patients undergoing second-look laparotomy after primary surgery and adjunctive chemotherapy was evaluated by retrospective chart review. From August 1976 to August 1987, 102 patients with stage I-IV disease underwent second-look laparotomy. Optimal tumor debulking and early (stage I or II) disease were positively correlated with a negative second-look laparotomy. Of the 49 patients with a "negative" second look, 15 demonstrated recurrent tumor from 12.5 to 52.5 months after laparotomy. Of the 15 recurrences, 6 were documented more than 3 years following second look. Half of the 28 patients with stage III disease and a "negative" second look have demonstrated recurrent tumor. Fifty-three patients (52%) were found to have residual disease at second-look laparotomy. Initial chemotherapy (melphalan or multiple agent) and the adequacy of primary debulking surgery (optimal vs suboptimal) were not significant factors contributing to patient survival after a positive second look. However, the size of residual disease at second-look laparotomy was a significant factor in subsequent patient survival (P ≤ 0.01). Fifteen patients were free of gross disease at laparotomy, but had residual tumor on microscopic examination of the specimens submitted. These patients had a 2-year actuarial survival of 78%. Forty-seven percent have survived 5 or more years after second look. Nineteen patients with tumor implants 2 cm or smaller had 2- and 5-year actuarial survivals of 61 and 31%, respectively. Nineteen patients with tumor nodules larger than 2 cm in diameter had a 2-year actuarial survival of 6%. Only 1 of 19 patients with nodules greater than 2 cm could be effectively redebulked.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalGynecologic Oncology
Volume36
Issue number1
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Laparotomy
Carcinoma
Survival
Neoplasms
Drug Therapy
Melphalan
Residual Neoplasm
Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. / Podczaski, Edward; Manetta, Alberto; Kaminski, Paul; Ricelli, Antonio; Larson, James; De Geest, Koenraad; Mortel, Rodrigue.

In: Gynecologic Oncology, Vol. 36, No. 1, 1990, p. 43-47.

Research output: Contribution to journalArticle

Podczaski, E, Manetta, A, Kaminski, P, Ricelli, A, Larson, J, De Geest, K & Mortel, R 1990, 'Survival of patients with ovarian epithelial carcinomas after second-look laparotomy', Gynecologic Oncology, vol. 36, no. 1, pp. 43-47. https://doi.org/10.1016/0090-8258(90)90106-U
Podczaski, Edward ; Manetta, Alberto ; Kaminski, Paul ; Ricelli, Antonio ; Larson, James ; De Geest, Koenraad ; Mortel, Rodrigue. / Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. In: Gynecologic Oncology. 1990 ; Vol. 36, No. 1. pp. 43-47.
@article{eedbd302e19c45f8aab0545c303d8644,
title = "Survival of patients with ovarian epithelial carcinomas after second-look laparotomy",
abstract = "Survival of ovarian carcinoma patients undergoing second-look laparotomy after primary surgery and adjunctive chemotherapy was evaluated by retrospective chart review. From August 1976 to August 1987, 102 patients with stage I-IV disease underwent second-look laparotomy. Optimal tumor debulking and early (stage I or II) disease were positively correlated with a negative second-look laparotomy. Of the 49 patients with a {"}negative{"} second look, 15 demonstrated recurrent tumor from 12.5 to 52.5 months after laparotomy. Of the 15 recurrences, 6 were documented more than 3 years following second look. Half of the 28 patients with stage III disease and a {"}negative{"} second look have demonstrated recurrent tumor. Fifty-three patients (52{\%}) were found to have residual disease at second-look laparotomy. Initial chemotherapy (melphalan or multiple agent) and the adequacy of primary debulking surgery (optimal vs suboptimal) were not significant factors contributing to patient survival after a positive second look. However, the size of residual disease at second-look laparotomy was a significant factor in subsequent patient survival (P ≤ 0.01). Fifteen patients were free of gross disease at laparotomy, but had residual tumor on microscopic examination of the specimens submitted. These patients had a 2-year actuarial survival of 78{\%}. Forty-seven percent have survived 5 or more years after second look. Nineteen patients with tumor implants 2 cm or smaller had 2- and 5-year actuarial survivals of 61 and 31{\%}, respectively. Nineteen patients with tumor nodules larger than 2 cm in diameter had a 2-year actuarial survival of 6{\%}. Only 1 of 19 patients with nodules greater than 2 cm could be effectively redebulked.",
author = "Edward Podczaski and Alberto Manetta and Paul Kaminski and Antonio Ricelli and James Larson and {De Geest}, Koenraad and Rodrigue Mortel",
year = "1990",
doi = "10.1016/0090-8258(90)90106-U",
language = "English (US)",
volume = "36",
pages = "43--47",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Survival of patients with ovarian epithelial carcinomas after second-look laparotomy

AU - Podczaski, Edward

AU - Manetta, Alberto

AU - Kaminski, Paul

AU - Ricelli, Antonio

AU - Larson, James

AU - De Geest, Koenraad

AU - Mortel, Rodrigue

PY - 1990

Y1 - 1990

N2 - Survival of ovarian carcinoma patients undergoing second-look laparotomy after primary surgery and adjunctive chemotherapy was evaluated by retrospective chart review. From August 1976 to August 1987, 102 patients with stage I-IV disease underwent second-look laparotomy. Optimal tumor debulking and early (stage I or II) disease were positively correlated with a negative second-look laparotomy. Of the 49 patients with a "negative" second look, 15 demonstrated recurrent tumor from 12.5 to 52.5 months after laparotomy. Of the 15 recurrences, 6 were documented more than 3 years following second look. Half of the 28 patients with stage III disease and a "negative" second look have demonstrated recurrent tumor. Fifty-three patients (52%) were found to have residual disease at second-look laparotomy. Initial chemotherapy (melphalan or multiple agent) and the adequacy of primary debulking surgery (optimal vs suboptimal) were not significant factors contributing to patient survival after a positive second look. However, the size of residual disease at second-look laparotomy was a significant factor in subsequent patient survival (P ≤ 0.01). Fifteen patients were free of gross disease at laparotomy, but had residual tumor on microscopic examination of the specimens submitted. These patients had a 2-year actuarial survival of 78%. Forty-seven percent have survived 5 or more years after second look. Nineteen patients with tumor implants 2 cm or smaller had 2- and 5-year actuarial survivals of 61 and 31%, respectively. Nineteen patients with tumor nodules larger than 2 cm in diameter had a 2-year actuarial survival of 6%. Only 1 of 19 patients with nodules greater than 2 cm could be effectively redebulked.

AB - Survival of ovarian carcinoma patients undergoing second-look laparotomy after primary surgery and adjunctive chemotherapy was evaluated by retrospective chart review. From August 1976 to August 1987, 102 patients with stage I-IV disease underwent second-look laparotomy. Optimal tumor debulking and early (stage I or II) disease were positively correlated with a negative second-look laparotomy. Of the 49 patients with a "negative" second look, 15 demonstrated recurrent tumor from 12.5 to 52.5 months after laparotomy. Of the 15 recurrences, 6 were documented more than 3 years following second look. Half of the 28 patients with stage III disease and a "negative" second look have demonstrated recurrent tumor. Fifty-three patients (52%) were found to have residual disease at second-look laparotomy. Initial chemotherapy (melphalan or multiple agent) and the adequacy of primary debulking surgery (optimal vs suboptimal) were not significant factors contributing to patient survival after a positive second look. However, the size of residual disease at second-look laparotomy was a significant factor in subsequent patient survival (P ≤ 0.01). Fifteen patients were free of gross disease at laparotomy, but had residual tumor on microscopic examination of the specimens submitted. These patients had a 2-year actuarial survival of 78%. Forty-seven percent have survived 5 or more years after second look. Nineteen patients with tumor implants 2 cm or smaller had 2- and 5-year actuarial survivals of 61 and 31%, respectively. Nineteen patients with tumor nodules larger than 2 cm in diameter had a 2-year actuarial survival of 6%. Only 1 of 19 patients with nodules greater than 2 cm could be effectively redebulked.

UR - http://www.scopus.com/inward/record.url?scp=0025136975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025136975&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90106-U

DO - 10.1016/0090-8258(90)90106-U

M3 - Article

VL - 36

SP - 43

EP - 47

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -